Harbour Antibodies Partners with Abveris, a Boston Drug Discovery CRO

Harbour
Published on: July 16, 2019
Author: Amy Liu

Harbour Antibodies, the Dutch drug discovery subsidiary of Harbour BioMed, partnered with Boston’s Abveris to offer its fully-human antibody discovery services together with Abveris’ therapeutic antibody discovery services. Under a Co-Offering Agreement, Averis will be able to offer clients a low-upfront evaluation fee and pre-negotiated commercial terms. This will allow Abveris clients to consider the Harbour’s H2L2 human transgenic mouse technology before committing to a commercial license. Headquartered in Boston, Harbour Bio has operations in Shanghai and Suzhou.

Source: China Biotoday

Biotechnology Life Science Medical Device Pharmaceutical